ArticleJournal of bone metabolism2017
Clinical Characteristics, Causes and Survival in 115 Cancer Patients with Parathyroid Hormone Related Protein-mediated Hypercalcemia.
Article in Journal of bone metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma.Frontiers in oncology · 2022Pooled it
- Parathyroid hormone-related protein-mediated hypercalcemia of malignancy: insights from a multicenter clinical data warehouse.The Korean journal of internal medicine · 2026Trial
- PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review.Archives of gynecology and obstetrics · 2026Article
- Case Report: Response to ivosidenib in patients with cholangiocarcinoma: a clinical perspective with illustrative cases.Frontiers in oncology · 2026Article
- Parathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study.JBMR plus · 2025Article
- Functional pancreatic neuroendocrine tumors predominantly presenting with hypercalcemia: a case report.Frontiers in oncology · 2025Article
- Case 16: A 75-Year-Old Man With Macroglossia and Hypercalcemia.Journal of Korean medical science · 2023Article
- Parathyroid Hormone-Related Protein Promotes the Proliferation of Patient-Derived Glioblastoma Stem Cells via Activating cAMP/PKA Signaling Pathway.International journal of stem cells · 2023Article
- Parathyroid Hormone Related Peptide Hypercalcemia as a Presentation of Endometrial Clear Cell Carcinoma.Journal of community hospital internal medicine perspectives · 2023Article
- Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases.Annals of hematology · 2020Review
- Physiological roles of parathyroid hormone-related protein.Acta bio-medica : Atenei Parmensis · 2019Review
- Cholangiocarcinoma in a Child with Progressive Abdominal Distension and Secondary Hypercalcemia.Case reports in pediatrics · 2018Article
- Parathyroid Hormone-Related Protein-Producing Adenocarcinoma Suspicious of Lung Cancer: A Case Report.Case reports in oncologyArticle
- Hypercalcemia Associated with Extramammary Paget's Disease.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to determine the proportion of cancers presenting with parathyroid hormone (PTH) related protein (PTHrP)-mediated hypercalcemia, examine the clinical and biochemical characteristics, identify predictive factors for survival. And we also compared those characteristics between solid organ and hematologic malignancy groups.
methodsCancer patients with PTHrP-mediated hypercalcemia who were treated at Chonnam National University Hospital in Korea from January 2005 to January 2015 were retrospectively reviewed.
resultsOf all 115 patients, solid organ malignancies were the most common etiology (98 cases, 85.2%), with squamous cell carcinoma (50 cases, 43.4%), adenocarcinoma (27 cases, 23.4%). Interestingly, hepatocellular carcinoma (HCC; 18 cases, 15.7%) and cholangiocarcinoma (11 cases, 9.6%) were much more common causes than other previous reports. Hematologic malignancy was less common (17 cases, 14.8%), with multiple myeloma (9 cases, 7.8%) and non-Hodgkin's lymphoma (5 cases, 4.3%). Overall median survival was only 37 days. There was significant difference in median survival between two groups (35 days for solid organ malignancy and 72 days for hematologic malignancy;
conclusionsPTHrP-mediated hypercalcemia was most frequently caused by solid organ malignancy. However, HCC and cholangiocarcinoma were important causes of PTHrP-mediated hypercalcemia may be due to geographic differences in cancer incidence in Korean population. Age, the type of malignancy and the time interval of developing hypercalcemia after cancer diagnosis were independent poor predictive factors for survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.